Characterization of Immune Response in Participants from a Posdinemab Study

2024-514634-20-00 Protocol NOPRODALZ0005 Human pharmacology (Phase I) - Other Ended

Start 25 Feb 2025 · End 9 Jan 2026 · Status Ended · 3 EU/EEA countries · 4 sites · Protocol NOPRODALZ0005

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 45
Countries 3
Sites 4

Early Alzheimer's disease

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
25 Feb 2025 → 9 Jan 2026
Decision date (initial)
2024-12-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Early Alzheimer's disease

VersionLevelCodeTermSystem organ class
20.0 PT 10012271 Dementia Alzheimer's type 100000004852
20.0 PT 10074616 Prodromal Alzheimer's disease 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

3 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 10 2
Netherlands Ended 5 1
Spain Ended 5 1
Rest of world
Canada, United States
25

Investigational sites

France

2 sites · Ended
Pellegrin Hospital
Neurology, Place Amelie Raba Leon, 33000, Bordeaux
Centre Hospitalier Universitaire De Lille
Neurology, Avenue Du Professeur Emile Laine, 59037, Lille Cedex

Netherlands

1 site · Ended
Brain Research Center Den Bosch B.V.
Brain Research Center Den Bosch / Jeroen Bosch Ziekenhuis, Statenlaan 37, 5223 LA, 's-Hertogenbosch

Spain

1 site · Ended
Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos
Servicio de Neurología, Calle Del Profesor Martin Lagos, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-03-25 2025-03-25 2026-01-08
Netherlands 2025-02-25 2025-02-25 2026-01-08
Spain 2025-11-24 2025-11-24 2026-01-08

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-30 Spain Acceptable
2024-12-16
2024-12-16
2 SUBSTANTIAL MODIFICATION SM-1 2025-04-16 Spain Acceptable
2025-05-22
2025-05-22